Telstran Plus

Per 40/12.5 mg tab Telmisartan 40 mg, hydrochlorothiazide 12.5 mg. Per 80/12.5 mg tab Telmisartan 80 mg, hydrochlorothiazide 12.5 mg

Essential HTN when BP is inadequately controlled by telmisartan monotherapy.

1 tab once daily. Severe HTN 160 mg alone or in combination w/ hydrochlorothiazide 12.5-25 mg daily. Mild to moderate hepatic impairment Not to exceed 40/12.5 mg once daily.

May be taken with or without food.

Hypersensitivity to telmisartan, hydrochlorothiazide or other sulphonamide-derived substances. Cholestasis, biliary obstructive disorders; refractory hypokalaemia, hypercalcaemia. Concomitant use w/ aliskiren-containing products in patients w/ DM or renal impairment (GFR <60 mL/min/1.73 m²). Severe hepatic & renal impairment (CrCl <30 mL/min). 2nd & 3rd trimesters of pregnancy.

Hypersensitivity w/ or w/o history of allergy or bronchial asthma. History of sulfonamide or penicillin allergy. Not be given in patients w/ cholestasis, biliary obstructive disorders. Not recommended in primary aldosteronism. Increased risk of non-melanoma skin cancer. Bilateral renal artery stenosis or artery stenosis to single functioning kidney; dual blockade of renin-angiotensin-aldosterone system, severe CHF or underlying renal disease including renal artery stenosis; aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy; hyperuricaemia or frank gout; fluid or electrolyte imbalance; hypo- & hyperkalaemia; heart failure, DM; hypercalcaemia; hypomagnesaemia; ischemic cardiopathy or CV disease; SLE exacerbation or activation; acute transient myopia, acute angle-closure glaucoma. May impair glucose tolerance. Avoid sunlight & UV rays exposure. Correct vol &/or Na depletion prior to administration. Periodically monitor serum electrolytes, K, creatinine & uric acid levels. Discontinue use prior to parathyroid function test. Black patients. Fructose & galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Concomitant use w/ corticosteroids, ACTH, K-sparing diuretics, K supplements, K-containing salt substitutes. Not be used in patients w/ severe hepatic insufficiency & renal impairment (CrCl <30 mL/min). Recent kidney transplant. Hepatic impairment or progressive hepatic disease. Mild to moderate renal impairment. Not recommended during 1st trimester of pregnancy & lactation. Childn & adolescents ≤18 yr.

Dizziness. Hydrochlorothiazide: Hypomagnesaemia; nausea.

Reversible increased serum lithium conc & toxicity. Potentiated effect on serum K w/ other kaliuretic diuretics, laxatives, corticosteroids, ACTH, amphotericin, carbenoxolone, penicillin G Na, salicylic acid & derivatives. Increased serum K w/ ACE inhibitors, K-sparing diuretics, K supplements, K-containing salt substitutes, cyclosporin, heparin Na. Drugs affected by serum K disturbances eg, digitalis glycosides, antiarrhythmics, drugs inducing Torsade de pointes. Digitalis-induced arrhythmia w/ digitalis glycosides. Increased digoxin peak plasma conc. Increased hypotensive effects of other antihypertensive agents. Dosage adjustment of antidiabetics eg, oral agents, insulins. Risk of lactic acidosis w/ metformin. Impaired absorption w/ anionic exchange resins. Reduced diuretic, natriuretic & antihypertensive effects w/ NSAIDs. Decreased pressor amines effect. Potentiated non-depolarizing skeletal muscle relaxants effect. Increased hypersensitivity reactions of allopurinol. Increased serum Ca levels. Enhanced β-blockers & diazoxide hyperglycemic effect. Increased bioavailability w/ anticholinergics eg, atropine, biperiden. Increased risk of adverse effects by amantadine. Reduced renal excretion & potentiated myelosuppressive effects of cytotoxic agents eg, cyclophosphamide, MTX.

Angiotensin II Antagonists / Diuretics

C09DA07 - telmisartan and diuretics ; Belongs to the class of angiotensin II receptor blockers (ARBs) in combination with diuretics. Used in the treatment of cardiovascular disease.

B